Drugs / Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage
Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage
also known as
TIVV-IB
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05779020 Comparator | Apr 2023 → Sep 2024 | influenza | Butantan Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05779020 ↗ |
| Known as | TIVV-IB | “The study interventions are the Butantan Quadrivalent Influenza Vaccine (split virion, inactivated) in two dose scheme (QIV-IB/0.25ml and QIV-IB/0.50ml) and the active controls...” NCT05779020 ↗ |
| Modality | Vaccine | “Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml” NCT05779020 ↗ |